Morgan Stanley analyst Sean Laaman maintained a Buy rating on CG Oncology, Inc. on September 5 and set a price target of $56.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors that highlight CG Oncology’s promising clinical results and competitive positioning. The recent update from CG Oncology showed a 24-month complete response (CR) rate of 41.8%, which exceeded previous expectations and demonstrated a best-in-disease profile compared to key competitors. This improvement in CR rates underscores the potential efficacy of their treatment, particularly in the HR BCG-unresponsive NMIBC space.
Furthermore, the company’s management has clarified that all patients pending a 24-month assessment remained in response, adding credibility to their clinical outcomes. The absence of severe treatment-related adverse events further strengthens the safety profile of their therapy. With the initiation of the Biologics License Application (BLA) submission on track for the fourth quarter of 2025, CG Oncology is well-positioned for future growth, making it an attractive investment opportunity.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $82.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGON in relation to earlier this year.